By Mrinalika Roy and Bhanvi Satija (Reuters) -As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly invests $3B in a Netherlands plant to produce obesity drug orforglipron, creating new jobs. Read more here.
Eli Lilly & Co. failed to prove in a federal court that a business selling copycat versions of its obesity drug causes harm ...
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on ...